Cytokinetics' stock drops after heart drug PDUFA pushed back due to lack of REMS

Cytokinetics said late Thursday that the PDUFA date for its heart disease therapy aficamten would be delayed by three months to Dec. 26. The lag would allow the FDA to review ...